GO:0035438 cyclic-di-GMP binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035438 cyclic-di-GMP binding is a molecular function defined as binding to cyclic dimeric guanosine monophosphate (c-di-GMP), a ubiquitous bacterial second messenger.
• c-di-GMP binding proteins use diverse domains such as PilZ, GGDEF, EAL, and c-di-GMP-specific riboswitches to sense the dinucleotide and transduce signals.
• c-di-GMP binding regulates bacterial biofilm formation, motility, cell cycle progression, virulence, and host immune responses.
• In eukaryotes, c-di-GMP can directly bind MD2 and trigger inflammation, linking this prokaryotic second messenger to acute lung injury.
• The cyanobacterial c-di-GMP effector CdgB controls cell size, showing that c-di-GMP binding influences fundamental cellular morphogenesis.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of c-di-GMP-binding proteins in bacteria and host cells.
Description
Cyclic-di-GMP binding (GO:0035438) is the molecular function of selectively and non-covalently interacting with cyclic dimeric guanosine monophosphate (c-di-GMP), a second messenger that is nearly universal in bacteria. The dinucleotide is synthesized from two GTP molecules by diguanylate cyclases (DGCs) and degraded by specific phosphodiesterases (PDEs), allowing rapid fluctuations in intracellular c-di-GMP levels that are decoded by c-di-GMP-binding effectors. Because c-di-GMP controls the transition between motile and sessile lifestyles, biofilm formation, and virulence, the proteins that bind it are central to bacterial physiology and pathogenesis. The importance of c-di-GMP binding extends beyond bacteria. Recent work shows that c-di-GMP can directly bind the host protein MD2 (also known as LY96), triggering inflammatory signaling and acute lung injury in mice. In cyanobacteria, a c-di-GMP-binding effector controls cell size, demonstrating that this molecular function impacts fundamental cellular morphogenesis. In Salmonella, c-di-GMP binding to the histone-like nucleoid-structuring protein H-NS inhibits its DNA-binding activity, revealing a direct link between c-di-GMP and global gene regulation. For researchers, GO:0035438 provides a precise annotation for any protein or RNA that physically interacts with c-di-GMP. Identifying and characterizing these binders is essential to understand how bacteria adapt to changing environments, how pathogens regulate virulence, and how the host immune system senses this dinucleotide. This article reviews the mechanisms, key genes, disease relevance, and experimental methods for studying cyclic-di-GMP binding.
cyclic-di-GMP binding At A Glance
| GO ID | GO:0035438 |
|---|---|
| GO term | cyclic-di-GMP binding |
| Ontology | molecular_function |
| Synonym | 3',5'-cyclic di-GMP binding; c-di-GMP binding; cyclic dinucleotide di-GMP binding |
| Definition | Binding to cyclic-di-GMP, cyclic dimeric guanosine monophosphate. |
| Major function | Sensing and transducing c-di-GMP signals in bacteria and host cells, regulating biofilm formation, motility, virulence, cell cycle, and immune responses. |
| Representative domains | PilZ, GGDEF, EAL, HD-GYP, c-di-GMP riboswitches, and MD2 (LY96) in eukaryotes. |
| Related second messenger | c-di-GMP is synthesized by diguanylate cyclases (DGCs) and degraded by phosphodiesterases (PDEs). |
| Taxonomic scope | Bacteria, with emerging evidence in eukaryotes (e.g., human MD2). |
What Is GO:0035438?
In the Gene Ontology, GO:0035438 cyclic-di-GMP binding is defined as the molecular function of binding to cyclic-di-GMP, cyclic dimeric guanosine monophosphate. It encompasses any selective, non-covalent interaction between a protein or RNA molecule and c-di-GMP, including binding by dedicated effector domains, riboswitches, and host immune receptors.
Why Is cyclic-di-GMP binding Important in Cell Biology?
Cyclic-di-GMP binding is a central node in bacterial signal transduction because it converts fluctuations in the intracellular concentration of c-di-GMP into diverse physiological outputs, including biofilm formation, motility, cell cycle progression, and virulence factor production. Many bacterial pathogens rely on c-di-GMP-binding effectors to switch between acute and chronic infection modes, making these proteins attractive targets for anti-virulence therapies. In addition, the discovery that c-di-GMP binds host MD2 to trigger inflammation highlights a direct role for this molecular function in human disease, particularly acute lung injury. Understanding the structural and functional diversity of c-di-GMP-binding proteins is therefore critical for microbiology, infectious disease research, and immunology.
• c-di-GMP binding controls the motile-to-sessile transition and biofilm formation in many bacteria.
• It regulates virulence gene expression in pathogens such as Salmonella, Legionella, and Pseudomonas.
• Diverse binding domains (PilZ, GGDEF, EAL, HD-GYP) allow integration of c-di-GMP signals into different cellular pathways.
• c-di-GMP binding to H-NS directly modulates global DNA binding and gene expression in Salmonella.
• In cyanobacteria, c-di-GMP binding by CdgB controls cell size, linking the second messenger to morphogenesis.
• Host MD2 binds c-di-GMP to induce inflammation and acute lung injury, expanding the relevance to human disease.
• c-di-GMP-binding proteins are potential targets for anti-biofilm and anti-virulence drugs.
• CRISPR screens and knockout models can identify and validate c-di-GMP-binding effectors in diverse species.
• Understanding c-di-GMP binding informs synthetic biology approaches to engineer bacterial behaviors.
• The evolutionary history of c-di-GMP signaling provides insights into bacterial adaptation and host-microbe interactions.
Molecular Mechanism of cyclic-di-GMP binding
c-di-GMP synthesis and turnover
In simple terms: c-di-GMP is made and broken down by specific enzymes, so its level can rise and fall quickly.
c-di-GMP is synthesized from two molecules of GTP by diguanylate cyclases (DGCs) containing GGDEF domains and is degraded by phosphodiesterases (PDEs) with EAL or HD-GYP domains. The opposing activities of DGCs and PDEs determine the intracellular concentration of c-di-GMP, which in turn dictates the occupancy and activity of c-di-GMP-binding effectors. This dynamic turnover allows bacteria to respond rapidly to environmental cues.
Diverse c-di-GMP-binding domains
In simple terms: Many different protein domains have evolved to grab c-di-GMP, each with a slightly different shape and function.
Structural and biochemical studies have identified multiple c-di-GMP-binding domains, including PilZ, GGDEF, EAL, HD-GYP, and various degenerate variants. Some proteins use these domains solely for binding, while others combine binding with enzymatic activity, as seen in GGDEF-EAL tandem proteins. The diversity of binding modes allows c-di-GMP to regulate a wide range of targets, from transcription factors to enzymes and structural proteins.
Allosteric regulation by c-di-GMP binding
In simple terms: When c-di-GMP attaches to a protein, it can change the protein's shape and turn its activity on or off.
Binding of c-di-GMP often induces conformational changes that modulate the activity of the target protein. For example, in Salmonella, c-di-GMP binding to H-NS inhibits its DNA-binding activity, thereby altering global gene expression. In Legionella pneumophila, the NosP protein modulates c-di-GMP signaling through its binding and enzymatic activities. Such allosteric regulation is a recurring theme in c-di-GMP-dependent control of bacterial physiology.
c-di-GMP riboswitches and RNA binding
In simple terms: Some RNA molecules can also bind c-di-GMP and change gene expression without making a protein.
In addition to proteins, certain bacteria use c-di-GMP-responsive riboswitches to regulate gene expression at the RNA level. These structured RNA elements bind c-di-GMP and control transcription termination or translation initiation, adding another layer to the c-di-GMP signaling network. Riboswitches provide a direct link between c-di-GMP concentration and downstream gene expression.
Host c-di-GMP binding and immune sensing
In simple terms: Even human cells can bind c-di-GMP, and when they do, it can trigger inflammation.
Recent evidence shows that c-di-GMP directly binds the host protein MD2 (LY96), leading to inflammatory signaling and acute lung injury in mice. This finding expands the functional scope of GO:0035438 beyond bacteria and suggests that c-di-GMP-binding proteins may serve as therapeutic targets in inflammatory diseases. The structural basis of c-di-GMP recognition by MD2 is an active area of research.
Key Genes Involved in GO:0035438 cyclic-di-GMP binding
The following genes and proteins represent key c-di-GMP-binding effectors and related factors across bacterial and host systems.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CdgB | c-di-GMP-binding effector controlling cell size in cyanobacteria | Model for c-di-GMP-dependent morphogenesis |
| H-NS | Histone-like nucleoid-structuring protein; binds c-di-GMP to modulate DNA binding | Global gene regulation in Salmonella |
| NosP | Heme-based sensor modulating c-di-GMP signaling in Legionella | Regulation of c-di-GMP turnover and virulence |
| MD2 (LY96) | Host protein that binds c-di-GMP and triggers inflammation | Acute lung injury and innate immunity |
| PilZ domain proteins | c-di-GMP-binding effectors involved in motility and biofilm formation | Widely used model for c-di-GMP binding |
| GGDEF domain proteins | Diguanylate cyclases with c-di-GMP-binding feedback | Synthesis and auto-regulation of c-di-GMP |
| EAL domain proteins | Phosphodiesterases that bind c-di-GMP | Degradation and signaling termination |
| HD-GYP domain proteins | c-di-GMP phosphodiesterases | Alternative degradation pathway |
| c-di-GMP riboswitches | RNA elements that bind c-di-GMP and regulate gene expression | RNA-level control of c-di-GMP responses |
| BcsA | Cellulose synthase with PilZ domain; binds c-di-GMP | Biofilm matrix production |
| FimX | c-di-GMP-binding protein involved in type IV pili assembly | Motility and surface sensing |
| LapD | c-di-GMP-binding protein regulating adhesin secretion | Biofilm formation |
| PgaD | c-di-GMP-binding protein for poly-N-acetylglucosamine synthesis | Biofilm matrix production |
| YcgR | c-di-GMP-binding protein that inhibits flagellar motility | Motility regulation |
| Clp | c-di-GMP-binding protein controlling virulence in Xanthomonas | Virulence and biofilm |
| CdgA | c-di-GMP-binding effector in cyanobacteria | Cell size control |
| STING | Host adaptor in c-di-GMP sensing pathways | Innate immune response to cyclic dinucleotides |
How Is cyclic-di-GMP binding Regulated?
The availability of c-di-GMP for binding is regulated by the opposing activities of diguanylate cyclases (GGDEF domain proteins) and phosphodiesterases (EAL or HD-GYP domain proteins), which control the intracellular concentration of the dinucleotide. Environmental signals such as oxygen, light, and host factors modulate these enzymes, thereby indirectly regulating c-di-GMP binding to effectors. In Legionella pneumophila, the NosP protein modulates c-di-GMP signaling through its heme-based sensing and phosphodiesterase activity. Additionally, c-di-GMP-binding proteins themselves can feedback on synthesis or degradation, as seen in GGDEF-EAL tandem proteins. In host cells, c-di-GMP binding to MD2 is regulated by the availability of the dinucleotide and the expression of MD2.
cyclic-di-GMP binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MD2 (LY96) | Acute lung injury and inflammation | Knockout mice, overexpression in lung epithelial cells |
| H-NS | Salmonella virulence and gene regulation | Salmonella knockout and point-mutation strains |
| NosP | Legionella pneumophila virulence | Legionella knockout and complementation |
| CdgB | Cyanobacterial cell size control | Cyanobacterial knockout and overexpression |
| PilZ domain proteins | Biofilm formation and motility | Bacterial knockout and c-di-GMP binding assays |
Bacterial virulence and biofilm-associated infections
c-di-GMP-binding proteins are central to the regulation of virulence and biofilm formation in many bacterial pathogens, including Salmonella, Legionella, and Pseudomonas. Biofilms are notoriously resistant to antibiotics and contribute to chronic infections, making c-di-GMP-binding effectors attractive targets for anti-virulence strategies. Disrupting c-di-GMP binding could therefore reduce bacterial pathogenicity without directly killing the bacteria.
Acute lung injury and inflammation
c-di-GMP directly binds the host protein MD2, inducing inflammatory responses and acute lung injury in mouse models. This finding links a bacterial second messenger to a severe human inflammatory condition and suggests that c-di-GMP-binding proteins may be therapeutic targets in acute respiratory distress syndrome. Further research is needed to fully elucidate the clinical relevance of this interaction.
Cell size control and morphogenesis
In cyanobacteria, the c-di-GMP-binding effector CdgB controls cell size, demonstrating that c-di-GMP binding can influence fundamental cellular morphogenesis. While this is not a human disease, it highlights the broad impact of c-di-GMP binding on cellular physiology and could inform studies of cell size regulation in other organisms.
From cyclic-di-GMP binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene bind c-di-GMP? | Recombinant protein with isothermal titration calorimetry (ITC) or DRaCALA |
| What is the effect of c-di-GMP binding on protein function? | Point mutations in the binding pocket (e.g., PilZ domain) |
| Does c-di-GMP binding regulate virulence in vivo? | Knockout of the effector gene in a bacterial pathogen, followed by infection models |
| Can c-di-GMP binding to host MD2 be targeted? | MD2 knockout mice or knock-in of binding-deficient MD2 |
| How does c-di-GMP binding affect global gene expression? | RNA-seq of wild-type vs. knockout bacteria |
| Can we visualize c-di-GMP binding in live cells? | Tagged knock-in of c-di-GMP-binding proteins with fluorescent proteins |
How to Study the cyclic-di-GMP binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry (ITC) | Binding affinity and stoichiometry | Validate c-di-GMP binding to purified proteins |
| DRaCALA | Direct binding in cell lysates | High-throughput screening of candidate binders |
| X-ray crystallography | Three-dimensional structure of protein-ligand complex | Define c-di-GMP binding pocket |
| RNA-seq | Global gene expression changes | Identify pathways regulated by c-di-GMP effectors |
| CRISPR knockout library | Gene essentiality and fitness | Discover novel c-di-GMP-related genes |
| Fluorescence microscopy | Subcellular localization and dynamics | Visualize tagged c-di-GMP-binding proteins |
| Western blot | Protein expression and stability | Confirm knockout or overexpression |
| qRT-PCR | Transcript levels of target genes | Validate RNA-seq results |
Biochemical binding assays
Isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), and DRaCALA are standard methods to measure direct binding between c-di-GMP and candidate proteins. These techniques provide quantitative affinity data and can be used to validate binding domain predictions. They are often combined with mutagenesis of the binding pocket to confirm specificity.
Structural biology
X-ray crystallography and cryo-electron microscopy have revealed the structural basis of c-di-GMP recognition by PilZ, GGDEF, and EAL domains. These structures show how c-di-GMP is coordinated and how binding induces conformational changes. Structural information guides the design of point mutations that abolish binding without affecting protein folding.
Transcriptomics and proteomics
RNA-seq and proteomics can be used to compare wild-type and c-di-GMP-binding-deficient strains, revealing downstream pathways controlled by the effector. For example, RNA-seq of Salmonella H-NS mutants showed global changes in gene expression upon c-di-GMP binding. Proteomic approaches can identify proteins that co-purify with c-di-GMP-binding effectors.
Genetic screens and CRISPR libraries
CRISPR knockout libraries can be used to systematically identify genes required for c-di-GMP-dependent phenotypes, such as biofilm formation or virulence. These screens can uncover novel c-di-GMP-binding proteins and regulatory pathways. Follow-up validation with individual knockouts and point mutations confirms causality.
How CRISPR Can Be Used to Study GO:0035438 cyclic-di-GMP binding
Knockout
CRISPR knockout of genes encoding c-di-GMP-binding proteins can reveal their physiological roles. For example, knocking out H-NS in Salmonella would disrupt c-di-GMP-dependent gene regulation. Knockout models are essential to determine whether a candidate gene is required for biofilm formation, motility, or virulence.
Point Mutation
Point mutations in the c-di-GMP-binding pocket can abolish binding without affecting protein stability, allowing precise dissection of binding-dependent functions. For instance, mutating key residues in a PilZ domain can prevent c-di-GMP binding and reveal downstream effects. Such models are valuable for distinguishing binding-dependent from binding-independent roles.
Knock-in
Knock-in of tagged c-di-GMP-binding proteins (e.g., with FLAG or GFP) enables localization and interaction studies in native contexts. Knock-in of binding-deficient alleles can serve as a control for binding specificity. In host cells, knock-in of MD2 mutants can test the role of c-di-GMP binding in inflammation.
Overexpression
Overexpression of c-di-GMP-binding proteins can amplify signaling outputs and facilitate biochemical purification. In bacteria, overexpression of a diguanylate cyclase or phosphodiesterase can alter c-di-GMP levels and indirectly affect binding. Overexpression models are useful for screening inhibitors of c-di-GMP binding.
How EDITGENE Supports cyclic-di-GMP binding Research
Researchers studying cyclic-di-GMP binding-related genes often need to determine whether a candidate gene is causally involved in c-di-GMP-dependent phenotypes, such as biofilm formation, virulence, or host inflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for cyclic-di-GMP binding research.
Frequently Asked Questions About cyclic-di-GMP binding
What is cyclic-di-GMP binding?
Cyclic-di-GMP binding (GO:0035438) is the molecular function of selectively interacting with cyclic dimeric guanosine monophosphate (c-di-GMP), a bacterial second messenger that regulates biofilm formation, motility, and virulence.
What genes are involved in cyclic-di-GMP binding?
Key genes include those encoding PilZ domain proteins, GGDEF and EAL domain proteins, H-NS, NosP, CdgB, and the host protein MD2 (LY96).
How does c-di-GMP binding regulate bacterial behavior?
c-di-GMP binding often induces conformational changes in effector proteins, altering their activity and downstream signaling to control processes like biofilm formation and motility.
Is cyclic-di-GMP binding relevant to human disease?
Yes, c-di-GMP can directly bind human MD2 to trigger inflammation and acute lung injury, linking this bacterial second messenger to human disease.
What are the main domains that bind c-di-GMP?
Common c-di-GMP-binding domains include PilZ, GGDEF, EAL, HD-GYP, and c-di-GMP-responsive riboswitches.
How can I study cyclic-di-GMP binding in the lab?
Biochemical assays such as ITC and DRaCALA, structural biology, and CRISPR-based genetic models are commonly used to study c-di-GMP binding.
What is the role of c-di-GMP in biofilm formation?
c-di-GMP binding to effectors such as BcsA and LapD promotes the production of biofilm matrix components and adhesins.
Can CRISPR be used to study c-di-GMP binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the functions of c-di-GMP-binding proteins.
What is the difference between c-di-GMP binding and c-di-GMP signaling?
c-di-GMP binding is the physical interaction between c-di-GMP and a target molecule, while signaling encompasses the entire pathway from synthesis to downstream responses.
Which pathogens rely on c-di-GMP binding for virulence?
Pathogens such as Salmonella, Legionella pneumophila, and Pseudomonas aeruginosa rely on c-di-GMP-binding effectors for virulence and biofilm formation.
Conclusion
Cyclic-di-GMP binding (GO:0035438) is a fundamental molecular function that enables bacteria and host cells to sense and respond to the second messenger c-di-GMP. The diversity of c-di-GMP-binding domains and effectors underscores its importance in regulating biofilm formation, motility, virulence, and even host inflammation. Understanding the structural and functional mechanisms of c-di-GMP binding is essential for developing new anti-virulence strategies and for deciphering host-microbe interactions. CRISPR-based genetic models, combined with biochemical and structural approaches, provide powerful tools to dissect the roles of individual c-di-GMP-binding proteins. EDITGENE offers comprehensive services to support these investigations, from knockout and point mutation to library screening and bioinformatics.
References
- 1. Chou SH et al.. 2016. Diversity of Cyclic Di-GMP-Binding Proteins and Mechanisms.. J Bacteriol 198(1):32-46 PMID: 26055114
- 2. Jenal U et al.. 2017. Cyclic di-GMP: second messenger extraordinaire.. Nat Rev Microbiol 15(5):271-284 PMID: 28163311
- 3. Römling U. 2023. Cyclic di-GMP signaling-Where did you come from and where will you go?. Mol Microbiol 120(4):564-574 PMID: 37427497
- 4. Qian C et al.. 2024. Cyclic-di-GMP induces inflammation and acute lung injury through direct binding to MD2.. Clin Transl Med 14(8):e1744 PMID: 39166890
- 5. Zeng X et al.. 2023. A c-di-GMP binding effector controls cell size in a cyanobacterium.. Proc Natl Acad Sci U S A 120(13):e2221874120 PMID: 36947515
- 6. Li S et al.. 2023. c-di-GMP inhibits the DNA binding activity of H-NS in Salmonella.. Nat Commun 14(1):7502 PMID: 37980414
- 7. Fischer JT et al.. 2019. NosP Modulates Cyclic-di-GMP Signaling in Legionella pneumophila.. Biochemistry 58(42):4325-4334 PMID: 31576744
- 8. Hall CL et al.. 2018. Cyclic-di-GMP regulation of virulence in bacterial pathogens.. Wiley Interdiscip Rev RNA 9(1) PMID: 28990312
